← All trials
NCT05667493
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Apr 30, 2029
- Completion date
- Aug 31, 2029
- First posted
- Dec 28, 2022
- Last posted
- Dec 28, 2022
- Enrollment
- 1400
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ionis Pharmaceuticals, Inc.Lead sponsor
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.